Anne Bachelot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Bachelot has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Touraine
P Touraine, Endocrinology and reproductive medicine, GH Pitie Salpetriere, Paris, 75651, France
11 shared publications M. Polak
6 shared publications- Joe-Elie Salem
Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale, CIC-2503, Assistance Publique-Hopitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, France
3 shared publications Jérôme Dulon
AP-HP, IE3M, hôpital Pitié-Salpêtrière, department of endocrinology and reproductive medicine and Centre de référence des maladies endocriniennes rares de la croissance, centre de référence des pathologies gynécologiques Rares, ICAN, Paris, France
3 shared publicationsMonique Leban
Department of Hormonal Biochemistry, AP‐HP Hôpital Pitié‐Salpêtrière Paris France
3 shared publicationsPhilippe Touraine
Department of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des Pathologies Gynécologiques Rares, AP‐HP, IE3M Hôpital Pitié‐Salpêtrière Paris France
3 shared publications
Latest Publications
- 1 September 2026
- Published by JLE in Médecine de la Reproduction
- Vol. 28 (3) , 00
How should insulin resistance be assessed and managed in patients with polyendocrine metabolic ovarian syndrome?
- 1 September 2026
- Published by JLE in Médecine de la Reproduction
- Vol. 28 (3) , 00
How should insulin resistance be assessed and managed in patients with polyendocrine metabolic ovarian syndrome?
- 17 November 2022
- Published by Wiley in Clinical Endocrinology
- Vol. 98 (3) , 315-322
Fertility and pregnancy outcomes in women with nonclassic 21‐hydroxylase deficiency
Introduction: Overall fertility and pregnancy outcomes in patients with nonclassic congenital adrenal hyperplasia (NCCAH) have been poorly studied. It has been suggested that hydrocortisone (HC) may decrease the time to conceive (TTC) and the rate of miscarriage in these patients.Objectives: To describe fertility and pregnancy outcomes in a large cohort of NCCAH women. The secondary objective was to identify factors that could impact reproductive outcomes, with a particular focus on HC dose and genetic status.Design: Retrospective study in a referral center for congenital adrenal hyperplasia.Patients and Measurements: One hundred seventy‐three female patients with NCCAH confirmed by genetic testing, followed in our center between 2010 and 2019.Results: Among the 173 patients, 95 women had a parental project, 86 of whom presented 176 pregnancies, 56% under glucocorticoid (GC) treatment and 44% without, and 76 women obtained 128 live births. Two‐thirds of the patients regularized their cycle under GC treatment, with significant decrease of androgens and progesterone levels. This treatment was associated with a shortening of TTC (coef β = −.196, information coefficient [IC] = [−10.7; −0.91], p = .021). Androgen levels and TTC were positively correlated to the rate of miscarriage (OR = 4.8, IC = [1.15; 20.34], p = .021 for testosterone, OR = 1.4, IC = [1.05; 1.81], p = .02 for androstenedione, and OR = 1.03, IC = [1.01; 1.06], p = .015 for TTC). There was no difference in terms of obstetric outcomes between patients with or without GC treatment. CYP21A2 genotype had no impact on pregnancy outcome or TTC.Conclusions: Infertility is relative in patients with NCCAH. HC seems beneficial for fertility and pregnancy outcomes, especially for patients with menstrual disorders and high preconceptional androgen levels.
- 17 November 2022
- Published by Wiley in Clinical Endocrinology
- Vol. 98 (3) , 315-322
Fertility and pregnancy outcomes in women with nonclassic 21‐hydroxylase deficiency
Introduction: Overall fertility and pregnancy outcomes in patients with nonclassic congenital adrenal hyperplasia (NCCAH) have been poorly studied. It has been suggested that hydrocortisone (HC) may decrease the time to conceive (TTC) and the rate of miscarriage in these patients.Objectives: To describe fertility and pregnancy outcomes in a large cohort of NCCAH women. The secondary objective was to identify factors that could impact reproductive outcomes, with a particular focus on HC dose and genetic status.Design: Retrospective study in a referral center for congenital adrenal hyperplasia.Patients and Measurements: One hundred seventy‐three female patients with NCCAH confirmed by genetic testing, followed in our center between 2010 and 2019.Results: Among the 173 patients, 95 women had a parental project, 86 of whom presented 176 pregnancies, 56% under glucocorticoid (GC) treatment and 44% without, and 76 women obtained 128 live births. Two‐thirds of the patients regularized their cycle under GC treatment, with significant decrease of androgens and progesterone levels. This treatment was associated with a shortening of TTC (coef β = −.196, information coefficient [IC] = [−10.7; −0.91], p = .021). Androgen levels and TTC were positively correlated to the rate of miscarriage (OR = 4.8, IC = [1.15; 20.34], p = .021 for testosterone, OR = 1.4, IC = [1.05; 1.81], p = .02 for androstenedione, and OR = 1.03, IC = [1.01; 1.06], p = .015 for TTC). There was no difference in terms of obstetric outcomes between patients with or without GC treatment. CYP21A2 genotype had no impact on pregnancy outcome or TTC.Conclusions: Infertility is relative in patients with NCCAH. HC seems beneficial for fertility and pregnancy outcomes, especially for patients with menstrual disorders and high preconceptional androgen levels.
- 27 April 2022
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 83 (3) , 181-185
Classical and non-classical congenital adrenal hyperplasia: What is the difference in subsequent fertility?
- 27 April 2022
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 83 (3) , 181-185
Classical and non-classical congenital adrenal hyperplasia: What is the difference in subsequent fertility?
- Open Access
- 14 October 2021
- Published by EDP Sciences in médecine/sciences
- Vol. 37 (10) , 882-887
Contraception dans le contexte de l’obésité
La question de l’influence de l’obésité sur la contraception peut être envisagée sous plusieurs angles : comme facteur de risque d’échec d’une contraception hormonale ; comme facteur de risque cardio-vasculaire, pouvant majorer ce risque lors de l’association à une contraception hormonale. Les modifications métaboliques observées au cours de l’obésité et la masse corporelle plus importante des femmes présentant une obésité peuvent en effet être à l’origine d’une réduction de l’efficacité de la contraception hormonale. Néanmoins, les données, mêmes peu nombreuses, laissent penser que l’efficacité de la plupart des méthodes de contraception n’est a priori pas diminuée chez ces femmes. La chirurgie bariatrique, utilisée pour remédier à l’obésité, constitue une situation complexe, qui impose une contraception dans la première année post-opératoire afin d’éviter toute grossesse. Si la technique chirurgicale induit une malabsorption (comme le bypass), toute contraception administrée par voie orale verra son efficacité fortement diminuée et sera donc déconseillée en raison d’un haut risque d’échec. Obese women are at high risk of unintended pregnancy. In addition, obesity is an important risk factor for venous thromboembolism events and arterial thrombosis. All of these data are to be considered in choosing a contraceptive method for obese women. The metabolic changes and the increased body mass of these women may be the cause of a reduction in the effectiveness of hormonal contraception. The progestin-only contraceptives (progestin only pills and etonogestrel subdermal implant) and the intra-uterine devices are the preferred contraceptive methods in women with obesity. The combined estrogen-progestin contraceptives may be proposed in young obese women without other cardiovascular risk factor. Obesity per se does not seem to increase the risk of failure of most contraceptive methods. Bariatric surgery is a complex situation. Contraception is needed for at least 12 months after surgery. Some bariatric surgery such as bypass can induce gastrointestinal malabsorption. In this situation, all oral contraceptives are not recommended because of a higher risk of failure.
- 14 October 2021
- Published by EDP Sciences in médecine/sciences
- Vol. 37 (10) , 882-887
Open AccessContraception dans le contexte de l’obésité
La question de l’influence de l’obésité sur la contraception peut être envisagée sous plusieurs angles : comme facteur de risque d’échec d’une contraception hormonale ; comme facteur de risque cardio-vasculaire, pouvant majorer ce risque lors de l’association à une contraception hormonale. Les modifications métaboliques observées au cours de l’obésité et la masse corporelle plus importante des femmes présentant une obésité peuvent en effet être à l’origine d’une réduction de l’efficacité de la contraception hormonale. Néanmoins, les données, mêmes peu nombreuses, laissent penser que l’efficacité de la plupart des méthodes de contraception n’est a priori pas diminuée chez ces femmes. La chirurgie bariatrique, utilisée pour remédier à l’obésité, constitue une situation complexe, qui impose une contraception dans la première année post-opératoire afin d’éviter toute grossesse. Si la technique chirurgicale induit une malabsorption (comme le bypass), toute contraception administrée par voie orale verra son efficacité fortement diminuée et sera donc déconseillée en raison d’un haut risque d’échec. Obese women are at high risk of unintended pregnancy. In addition, obesity is an important risk factor for venous thromboembolism events and arterial thrombosis. All of these data are to be considered in choosing a contraceptive method for obese women. The metabolic changes and the increased body mass of these women may be the cause of a reduction in the effectiveness of hormonal contraception. The progestin-only contraceptives (progestin only pills and etonogestrel subdermal implant) and the intra-uterine devices are the preferred contraceptive methods in women with obesity. The combined estrogen-progestin contraceptives may be proposed in young obese women without other cardiovascular risk factor. Obesity per se does not seem to increase the risk of failure of most contraceptive methods. Bariatric surgery is a complex situation. Contraception is needed for at least 12 months after surgery. Some bariatric surgery such as bypass can induce gastrointestinal malabsorption. In this situation, all oral contraceptives are not recommended because of a higher risk of failure.
- 1 March 2021
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 184 (3) , 365-371
Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients
We conducted a retrospective study on the long-term effect of mitotane treatment on testicular adrenal rest tumors (TARTs) in five adult patients with classic 21-hydroxylase deficiency. After 60 months of mitotane treatment, a decrease in adrenal steroids was observed in four patients. Testicular ultrasonography showed complete disappearance of TART in two patients, stabilization in two patients and a halving of TART volume in the remaining patient. Sperm count improved notably in two patients who had normal baseline inhibin B levels and small inclusions, thus enabling cryopreservation of the subjects’ semen. Four years of follow-up of these two patients after the withdrawal of mitotane showed no recurrence of TART and persistent normal testicular function. In conclusion, mitotane could be used as a last resort in CAH patients in the cases of azoospermia associated with TARTs but normal inhibin B levels, as it can improve long-term endocrine and exocrine testicular function.
- 1 March 2021
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 184 (3) , 365-371
Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients
We conducted a retrospective study on the long-term effect of mitotane treatment on testicular adrenal rest tumors (TARTs) in five adult patients with classic 21-hydroxylase deficiency. After 60 months of mitotane treatment, a decrease in adrenal steroids was observed in four patients. Testicular ultrasonography showed complete disappearance of TART in two patients, stabilization in two patients and a halving of TART volume in the remaining patient. Sperm count improved notably in two patients who had normal baseline inhibin B levels and small inclusions, thus enabling cryopreservation of the subjects’ semen. Four years of follow-up of these two patients after the withdrawal of mitotane showed no recurrence of TART and persistent normal testicular function. In conclusion, mitotane could be used as a last resort in CAH patients in the cases of azoospermia associated with TARTs but normal inhibin B levels, as it can improve long-term endocrine and exocrine testicular function.
- Open Access
- 2 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1464
Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias
Significant variations from the normal QT interval range of 350 to 450 milliseconds (ms) in men and 360 to 460 ms in women increase the risk for ventricular arrhythmias. This difference in the QT interval between men and women has led to the understanding of the influence of sex hormones on the role of gender-specific channelopathies and development of ventricular arrhythmias. The QT interval, which represents the duration of ventricular repolarization of the heart, can be affected by androgen levels, resulting in a sex-specific predilection for acquired and inherited channelopathies such as acquired long QT syndrome in women and Brugada syndrome and early repolarization syndrome in men. Manipulation of the homeostasis of these sex hormones as either hormonal therapy for certain cancers, recreational therapy or family planning and in transgender treatment has also been shown to affect QT interval duration and increase the risk for ventricular arrhythmias. In this review, we highlight the effects of endogenous and exogenous sex hormones in the physiological and pathological states on QTc variation and predisposition to gender-specific pro-arrhythmias.
- 2 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1464
Open AccessSexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias
Significant variations from the normal QT interval range of 350 to 450 milliseconds (ms) in men and 360 to 460 ms in women increase the risk for ventricular arrhythmias. This difference in the QT interval between men and women has led to the understanding of the influence of sex hormones on the role of gender-specific channelopathies and development of ventricular arrhythmias. The QT interval, which represents the duration of ventricular repolarization of the heart, can be affected by androgen levels, resulting in a sex-specific predilection for acquired and inherited channelopathies such as acquired long QT syndrome in women and Brugada syndrome and early repolarization syndrome in men. Manipulation of the homeostasis of these sex hormones as either hormonal therapy for certain cancers, recreational therapy or family planning and in transgender treatment has also been shown to affect QT interval duration and increase the risk for ventricular arrhythmias. In this review, we highlight the effects of endogenous and exogenous sex hormones in the physiological and pathological states on QTc variation and predisposition to gender-specific pro-arrhythmias.
- Open Access
- 17 May 2020
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (8) , 696-701
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may also trigger autoimmune adverse drug reactions (ADRs) referred to as immune-related adverse events (irAEs). Although endocrinopathies are among the most common form of irAEs, primary adrenal insufficiency (PAI) is infrequent and has only been published in case reports. The aim of this study was to identify and characterize the main features of PAI-irAE. Materials and Methods: Suspected PAI-irAE cases were identified using VigiBase, the World Health Organization's pharmacovigilance database of individual case safety reports. Results: From September 2, 2008, through October 5, 2018, a total of 50,108 ICI-associated ADRs were reported. Since 2008, there were 451 cases of PAI-irAE identified of which 45 were “definite PAI” and 406 “possible PAI.” Patients were mainly male (58.1%) with a median age of 66 years (range, 30–95). Indications of ICI were predominantly for melanoma (41.2%) and lung cancer (28.6%). The majority of patients were treated with ICI monotherapy (nivolumab: 44.3%, pembrolizumab: 11.7%, ipilimumab: 23.6%), and 17.9% were treated with ICI combination therapy. These events occurred with a median time to onset of 120 days (range, 6–576). ICI-associated PAI was associated with significant morbidity (≥90% severe) and mortality (7.3%). Fatality rates were similar in the subgroups of combination therapy versus monotherapy. There were no relevant differences in clinical or demographical characteristics and outcomes between “definite” versus “possible” PAI group. Conclusion: Our study represents the largest clinical description and characterization of PAI-irAE. Although ICI-associated PAI is a rare adverse event, early recognition is important to implement corticosteroid treatment. Further studies are required to elucidate risk factors and reversibility of this rare but severe irAE. Clinical trial identification number. NCT03492242 Implications for Practice: Immune checkpoint inhibitor (ICI)-associated primary adrenal insufficiency (PAI) is a rare adverse event that is important to recognize because it may be severe and life-threatening, requiring emergent and often lifelong hormonal replacement therapy. Awareness regarding this ICI-related endocrinopathy is strongly encouraged among clinicians in addition to patient education about common PAI symptoms that should prompt urgent medical evaluation. In clinical practice, close monitoring and investigation for PAI is crucial to allow for early management and to further define the pathophysiology and prognosis of ICI-PAI. Corticotrophin (adrenocorticotrophic hormone) circulating level evaluation may be often lacking but should be considered as part of the diagnostic workup to differentiate PAI from secondary (central) adrenal insufficiency.
- 17 May 2020
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (8) , 696-701
Open AccessImmune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may also trigger autoimmune adverse drug reactions (ADRs) referred to as immune-related adverse events (irAEs). Although endocrinopathies are among the most common form of irAEs, primary adrenal insufficiency (PAI) is infrequent and has only been published in case reports. The aim of this study was to identify and characterize the main features of PAI-irAE. Materials and Methods: Suspected PAI-irAE cases were identified using VigiBase, the World Health Organization's pharmacovigilance database of individual case safety reports. Results: From September 2, 2008, through October 5, 2018, a total of 50,108 ICI-associated ADRs were reported. Since 2008, there were 451 cases of PAI-irAE identified of which 45 were “definite PAI” and 406 “possible PAI.” Patients were mainly male (58.1%) with a median age of 66 years (range, 30–95). Indications of ICI were predominantly for melanoma (41.2%) and lung cancer (28.6%). The majority of patients were treated with ICI monotherapy (nivolumab: 44.3%, pembrolizumab: 11.7%, ipilimumab: 23.6%), and 17.9% were treated with ICI combination therapy. These events occurred with a median time to onset of 120 days (range, 6–576). ICI-associated PAI was associated with significant morbidity (≥90% severe) and mortality (7.3%). Fatality rates were similar in the subgroups of combination therapy versus monotherapy. There were no relevant differences in clinical or demographical characteristics and outcomes between “definite” versus “possible” PAI group. Conclusion: Our study represents the largest clinical description and characterization of PAI-irAE. Although ICI-associated PAI is a rare adverse event, early recognition is important to implement corticosteroid treatment. Further studies are required to elucidate risk factors and reversibility of this rare but severe irAE. Clinical trial identification number. NCT03492242 Implications for Practice: Immune checkpoint inhibitor (ICI)-associated primary adrenal insufficiency (PAI) is a rare adverse event that is important to recognize because it may be severe and life-threatening, requiring emergent and often lifelong hormonal replacement therapy. Awareness regarding this ICI-related endocrinopathy is strongly encouraged among clinicians in addition to patient education about common PAI symptoms that should prompt urgent medical evaluation. In clinical practice, close monitoring and investigation for PAI is crucial to allow for early management and to further define the pathophysiology and prognosis of ICI-PAI. Corticotrophin (adrenocorticotrophic hormone) circulating level evaluation may be often lacking but should be considered as part of the diagnostic workup to differentiate PAI from secondary (central) adrenal insufficiency.
- 1 January 2019
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 37 (1) , 175-181
Early central blood pressure elevation in adult patients with 21-hydroxylase deficiency
Context: Controversial data exist on cardiovascular damages in patients with congenital adrenal hyperplasia (CAH). Objective: To assess blood pressure and early cardiovascular damages on a large cohort of adult CAH patients and control individuals. Design: Case–control study. Setting: Referral Center for Rare Disease, Pitié Salpêtrière Hospital, Paris, France. Patients or other participants: Fifty-eight women and 26 men with CAH diagnosed in childhood and 85 controls matched-paired for sex, age and smoking status were prospectively included. Intervention: Measurement of large arteries and microcirculatory anatomical and functional indices as well as hormonal status and cardiovascular risk factors evaluation. Main outcome measure: The primary objective was to compare carotid intima–media thickness (cIMT) in CAH patients and controls. The secondary objectives were to compare blood pressure (BP), radial augmentation index (rAI), central BP, carotid–femoral pulse wave velocity (PWV), skin microcirculation indices and inflammation parameters in CAH patients and controls. Results: Although PWV and cIMT were identical in patients and controls, higher rAI (64.6 ± 1.7 vs. 59.9 ± 1.6%, P = 0.02) and higher central SBP (101.8 ± 1.5 vs. 95.1 ± 1.5 mmHg, P < 0.001) were observed in CAH patients. Regarding microcirculatory indices, there was a higher functional resting capacity and a lower anatomical capillary density in CAH patients. In multivariate analysis, we found an independant association between CAH and central SBP elevation. Conclusion: We found an early rise in central SBP in CAH patients whereas sublinical arterial damages markers were normal. Our study suggest that vascular damages and increased cardiovascular risk could be mainly BP-driven.
- 1 January 2019
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 37 (1) , 175-181
Early central blood pressure elevation in adult patients with 21-hydroxylase deficiency
Context: Controversial data exist on cardiovascular damages in patients with congenital adrenal hyperplasia (CAH). Objective: To assess blood pressure and early cardiovascular damages on a large cohort of adult CAH patients and control individuals. Design: Case–control study. Setting: Referral Center for Rare Disease, Pitié Salpêtrière Hospital, Paris, France. Patients or other participants: Fifty-eight women and 26 men with CAH diagnosed in childhood and 85 controls matched-paired for sex, age and smoking status were prospectively included. Intervention: Measurement of large arteries and microcirculatory anatomical and functional indices as well as hormonal status and cardiovascular risk factors evaluation. Main outcome measure: The primary objective was to compare carotid intima–media thickness (cIMT) in CAH patients and controls. The secondary objectives were to compare blood pressure (BP), radial augmentation index (rAI), central BP, carotid–femoral pulse wave velocity (PWV), skin microcirculation indices and inflammation parameters in CAH patients and controls. Results: Although PWV and cIMT were identical in patients and controls, higher rAI (64.6 ± 1.7 vs. 59.9 ± 1.6%, P = 0.02) and higher central SBP (101.8 ± 1.5 vs. 95.1 ± 1.5 mmHg, P < 0.001) were observed in CAH patients. Regarding microcirculatory indices, there was a higher functional resting capacity and a lower anatomical capillary density in CAH patients. In multivariate analysis, we found an independant association between CAH and central SBP elevation. Conclusion: We found an early rise in central SBP in CAH patients whereas sublinical arterial damages markers were normal. Our study suggest that vascular damages and increased cardiovascular risk could be mainly BP-driven.
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 237
L’hypogonadisme peut être un facteur de risque de torsade de pointes chez l’homme
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 237
L’hypogonadisme peut être un facteur de risque de torsade de pointes chez l’homme
- 1 September 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (4) , 228
Insuffisance ovarienne prématurée : analyse génétique par next generation sequencing (NGS) chez 288 patientes
- 1 September 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (4) , 228
Insuffisance ovarienne prématurée : analyse génétique par next generation sequencing (NGS) chez 288 patientes